These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 38162667)

  • 1. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Marks S; Naidoo J
    Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
    Chen X; Zeng C
    Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
    Somme LB; Chouaid C; Moinard-Butot F; Barbe-Richaud JB; Greillier L; Schott R
    BioDrugs; 2024 Jul; 38(4):487-497. PubMed ID: 38767823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation.
    Zhao C; Zhang R; Yang H; Gao Y; Zou Y; Zhang X
    Biochem Pharmacol; 2024 Aug; 226():116378. PubMed ID: 38908529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A narrative review of antibody-drug conjugates in
    Hsu R; Benjamin DJ
    Front Oncol; 2023; 13():1252652. PubMed ID: 38107063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
    Najjar MK; Manore SG; Regua AT; Lo HW
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
    Riudavets M; Sullivan I; Abdayem P; Planchard D
    ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Reuss JE; Gosa L; Liu SV
    Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.